

SKIPPirr: Evaluating Prophylactic Strategies to Reduce the Incidence of IRRs With Amivantamab

Rationale

- In CHRYSALIS, a phase 1 study, **IV amivantamab** has an IRR incidence of ~67% at first infusion^{1,a}
- Standard mitigation approaches in clinical trials include a **split first dose of amivantamab over 2 days in the first cycle** and premedication with oral or IV antihistamines, oral or IV antipyretics, and IV glucocorticoids²

SKIPPirr Study Design

SKIPPirr is a phase 2 prospective study (NCT05663866) that assesses prophylactic strategies administered prior to amivantamab infusion in order to reduce the incidence and/or severity of first-dose IRRs. This Simon's 2-stage study design evaluates prophylactic approaches in 4 cohorts, with the dexamethasone 8 mg oral cohort reaching the expansion stage.^b

Limitation:

- The dexamethasone 8 mg oral cohort sample size is n=40. Further studies are needed to determine prophylactic regimens

Key Eligibility Criteria

- EGFR Ex19del or L858R advanced/metastatic NSCLC
- Progression after prior osimertinib and prior platinum-based chemotherapy
- ECOG PS 0-1

Prophylactic IRR Approaches

- Dexamethasone (4 mg)**
Oral BID on Day -1 (2 doses total)
- Dexamethasone (8 mg)**
Oral BID on Days -2 and -1 before C1, and 1 dose 1h before C1D1 infusion (5 doses total)
- Montelukast (10 mg)**
Oral on Days -4, -3, -2, -1 and C1D1 before infusion (5 doses total)
- Methotrexate (25 mg)**
SC between Days -7 to -3 (1 dose total)

All patients also received standard IRR management

Anticancer Therapies

- IV amivantamab^c**
1050 mg
- Oral lazertinib^d**
240 mg once daily

Primary Endpoint

Incidence of IRR events on Cycle 1, Day 1^e

One cohort tested in SKIPPirr reached the expansion stage: dexamethasone 8 mg oral cohort³

Prophylactic schedule

AT HOME

2 days before
(Week 1, Day -2)

AM PM
4 mg 4 mg 4 mg 4 mg
Dexamethasone
2 tablets twice daily
(16 mg total daily dose)

1 day before
(Week 1, Day -1)

AM PM
4 mg 4 mg 4 mg 4 mg
Dexamethasone
2 tablets twice daily
(16 mg total daily dose)

Adequate oral hydration is encouraged throughout the prophylaxis period

IN CLINIC C1D1

1 hour before first
amivantamab infusion
(Week 1, Day 1)

4 mg 4 mg
Dexamethasone
4 mg x2 oral
+ dexamethasone 10 mg IV
+ antihistamines + antipyretics

IV
amivantamab
+
lazertinib

In SKIPPirr, the Week 1, Day 1 dexamethasone dose is 10 mg IV. In the amivantamab Prescribing Information, the Week 1, Day 1 dexamethasone dose is 20 mg IV.^{2,3}

Rate of IRRs on C1D1

67.4%
Standard IRR management¹
(historic; 256/380)

22.5% (95% CI, 10.8-38.5)
Dexamethasone 8 mg
IRR prophylaxis
(9/40)

SKIPPirr is not a comparative study. Please refer to the limitation section for additional information.

No grade ≥3 IRRs with dexamethasone 8 mg prophylaxis vs 2% with standard IRR management

- The most common IRR-related symptoms were nausea (8%), dyspnea (5%), and hypotension (5%). All symptoms were grade 1-2 (no grade ≥3)

^aBased on an analysis of the CHRYSALIS study.

^bStage 1 n=6. Stage 2 n=16. Expansion stage n=40. See full presentation for more details.

^cIV amivantamab: 1050 mg (1400 if ≥80 kg) once weekly for 4 weeks and then every 2 weeks thereafter.

^dAdminister lazertinib any time prior to amivantamab when given on the same day.

^eDefined as IRR events with onset within 24 hours of the start of the C1D1 amivantamab infusion and prior to the start of the C1D2 infusion.

1. Park K, et al. *Lung Cancer*. 2023;178:166-171. 2. RYBREVANT® (amivantamab-vmjw) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 3. Lopes G, et al. Presented at the World Conference on Lung Cancer (WCLC); September 7-10, 2024; San Diego, CA, USA.